Quantcast

Latest Centocor Stories

2014-04-29 08:36:39

NEW BRUNSWICK, N.J., April 29, 2014 /PRNewswire/ -- Johnson & Johnson today announced that its affiliate Janssen Pharmaceutica NV (Janssen) has entered into a novel collaboration with the Stichting International Dispensary Association (IDA), a procurement agent for the Stop TB Partnership's Global Drug Facility (GDF), to facilitate access to the Company's anti-tuberculosis medicine. This public-private partnership was established by the newly formed Janssen Global Public Health...

2014-04-23 16:29:12

NEW BRUNSWICK, N.J., April 23, 2014 /PRNewswire/ -- Johnson & Johnson (NYSE: JNJ) will host a review of its Medical Devices & Diagnostics business for the investment community beginning at 9:30 a.m. (Eastern Time) on Thursday, May 22, 2014 at the Hyatt Regency Hotel in New Brunswick, New Jersey and ending at approximately 2:30 p.m. Dominic J. Caruso, Vice President, Finance and Chief Financial Officer will host the meeting which will feature presentations by Johnson &...

2014-03-24 08:28:42

Results from Phase 2b X-PLORE Study through Week 40 Report Efficacy of Guselkumab across Multiple Dosing Regimens and Compared with Adalimumab DENVER, March 24, 2014 /PRNewswire/ -- New findings presented for the first time at the 2014 Annual Meeting of the American Academy of Dermatology (AAD) showed up to 86 percent of patients with moderate to severe plaque psoriasis receiving guselkumab (CNTO 1959) achieved a Physician's Global Assessment (PGA) score of cleared or minimal at week 16, the...

2014-03-21 23:03:40

ResearchMoz.us include new market research report "PharmaPoint: Crohns Disease - China Drug Forecast and Market Analysis to 2022" to its huge collection of research reports. Browse full report - http://www.researchmoz.us/pharmapoint-crohns-disease-china-drug-forecast-and-market-analysis-to-2022-report.html. Albany, NY (PRWEB) March 21, 2014 The Crohns disease (CD) market is currently very dynamic, with novel biologic therapies on the horizon. These compounds will challenge the...

2014-02-25 08:31:42

NEW BRUNSWICK, N.J., Feb. 25, 2014 /PRNewswire/ -- Johnson & Johnson (NYSE: JNJ) will participate in the 2014 Cowen 34(th) Annual Health Care Conference on Tuesday, Mar. 4, at The Boston Marriott Copley Place. Dominic Caruso, Vice President, Finance & Chief Financial Officer will represent the Company in a session scheduled at 10:00 a.m. (Eastern Time). This webcast will be available to investors and other interested parties by accessing the Johnson & Johnson website at...

2014-02-19 12:28:56

NEW YORK, LONDON, BERLIN, PARIS, February 19, 2014 /PRNewswire/ -- Reportstack has announced a newly published market intelligence report on Ulcerative Colitis - Global Drug Forecast and Market Analysis to 2022 [http://www.reportstack.com/product/150599/pharmapoint-ulcerative-colitis-global-drug-forecast-and-market-analysis-to-2022.html ] . The global ulcerative colitis (UC) market value will increase steadily over the coming years, growing from almost $4.2 billion in 2012...

2014-02-14 08:26:03

NEW BRUNSWICK, N.J., Feb. 14, 2014 /PRNewswire/ -- Johnson & Johnson (NYSE: JNJ) will participate in the 2014 Citi Global Health Care Conference on Monday, Feb. 24, at the Hilton New York Hotel in New York, NY. Joaquin Duato, Worldwide Chairman, Pharmaceuticals, will represent the Company as the keynote speaker, and is scheduled to present at 8:00 a.m. (Eastern). This webcast will be available to investors and other interested parties by accessing the Johnson & Johnson...

2014-02-06 23:24:53

MarketResearchReports.Biz announces addition of new report “Systemic Psoriasis Therapeutics in Major Developed Markets to 2020 - Continued Uptake of Biologics and Novel Pipeline Drugs to Drive Growth Description” to its database. Visit: http://www.marketresearchreports.biz/analysis/186872 Albany, NY (PRWEB) February 06, 2014 Systemic Psoriasis Therapeutics in Major Developed Markets to 2020 - Continued Uptake of Biologics and Novel Pipeline Drugs to Drive Growth Description Research...

2014-01-06 08:25:32

PRINCETON, N.J., Jan. 6, 2014 /PRNewswire/ -- Soligenix, Inc. (OTCQB: SNGX) (Soligenix or the Company), a clinical stage biopharmaceutical company focused on developing products to treat serious inflammatory diseases where there remains an unmet medical need, as well as developing several biodefense vaccines and therapeutics, announced today that it has appointed Richard Straube, MD, as its Senior Vice President and Chief Medical Officer. Dr. Straube is a board-certified...

2014-01-02 08:23:19

NEW BRUNSWICK, N.J., Jan. 2, 2014 /PRNewswire/ -- Johnson & Johnson (NYSE: JNJ) today announced that its Board of Directors has declared a cash dividend for the first quarter of 2014 of $0.66 per share on the company's common stock. The dividend is payable on March 11, 2014 to shareholders of record at the close of business on February 25, 2014. The ex-dividend date is February 21, 2014. About Johnson & Johnson Caring for the world, one person at a time...inspires and...


Word of the Day
omadhaun
  • A fool; a simpleton: a term of abuse common in Ireland and to a less extent in the Gaelic-speaking parts of Scotland.
This word is partly Irish in origin.